632
Views
12
CrossRef citations to date
0
Altmetric
Commentary

Optimizing insulin pump therapy: the potential advantages of using a structured diabetes management program

, , , , , , , , , , , & show all
Pages 477-485 | Accepted 06 Jan 2015, Published online: 11 Feb 2015
 

Abstract

Use of continuous subcutaneous insulin infusion (CSII) therapy improves glycemic control, reduces hypoglycemia and increases treatment satisfaction in individuals with diabetes. As a number of patient- and clinician-related factors can hinder the effectiveness and optimal usage of CSII therapy, new approaches are needed to address these obstacles.

Ceriello and colleagues recently proposed a model of care that incorporates the collaborative use of structured SMBG into a formal approach to personalized diabetes management within all diabetes populations. We adapted this model for use in CSII-treated patients in order to enable the implementation of a workflow structure that enhances patient–physician communication and supports patients’ diabetes self-management skills.

We recognize that time constraints and current reimbursement policies pose significant challenges to healthcare providers integrating the Personalised Diabetes Management (PDM) process into clinical practice. We believe, however, that the time invested in modifying practice workflow and learning to apply the various steps of the PDM process will be offset by improved workflow and more effective patient consultations. This article describes how to implement PDM into clinical practice as a systematic, standardized process that can optimize CSII therapy.

Transparency

Declaration of funding

Funding for the development of this manuscript was provided by Roche Diagnostics GmbH, Mannheim, Germany.

Declaration of financial/other relationships

K.L., R.Z., A.N., T.R., I.D., M.W., M.M., O.S., B.K., A.R., L.H. and T.H. have disclosed that they are members of an advisory board of Roche Diagnostics GmbH, Mannheim, Germany, receiving honoraria for participation and advice. C.G.P. has disclosed that he has received consulting fees from Roche Diagnostics GmbH.

CMRO peer reviewers on this manuscript have received an honorarium from CMRO for their review work, but have no relevant financial or other relationships to disclose.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.